within Pharmacolibrary.Drugs.ATC.B;

model B01AC11
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0003333333333333333,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0005200000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00061,
    k12             = 23,
    k21             = 23
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AC11</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Iloprost is a synthetic analogue of prostacyclin (PGI2), used as a vasodilator and inhibitor of platelet aggregation. It is primarily indicated for the treatment of pulmonary arterial hypertension (PAH), Raynaud's phenomenon, and critical limb ischemia. Iloprost is approved and in use today as an inhalation or intravenous therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adults receiving intravenous iloprost infusion.</p><h4>References</h4><ol><li><p>Hildebrand, M, et al., &amp; Bolognesi, M (1990). Pharmacokinetics of iloprost in patients with hepatic dysfunction. <i>International journal of clinical pharmacology, therapy, and toxicology</i> 28(10) 430–434. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1701761/&quot;>https://pubmed.ncbi.nlm.nih.gov/1701761</a></p></li><li><p>Hildebrand, M, et al., &amp; Neumayer, HH (1990). Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis. <i>International journal of clinical pharmacology research</i> 10(5) 285–292. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1706685/&quot;>https://pubmed.ncbi.nlm.nih.gov/1706685</a></p></li><li><p>Schermuly, RT, et al., &amp; Seeger, W (2002). Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. <i>The Journal of pharmacology and experimental therapeutics</i> 303(2) 741–745. DOI:<a href=&quot;https://doi.org/10.1124/jpet.303.2.741&quot;>10.1124/jpet.303.2.741</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12388660/&quot;>https://pubmed.ncbi.nlm.nih.gov/12388660</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AC11;
